Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Figure 5

The meta-analysis results for serious adverse reaction incidence rates after afatinib treatment in advanced NSCLC with EGFR mutation: (a) the adverse reaction incidence rate of diarrhea; (b) the adverse reaction incidence rate of mucositis; (c) the adverse reaction incidence rate of skin rashes; and (d) the adverse reaction incidence rate of paronychia.

(a)

(b)

(c)

(d)